Ascentage Pharma Group International: all 53 studies

Page 1 of 1. Open to participants first (31), then studies with results posted, then the rest; newest registration first within each.

• A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1
• Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentRecruitingNCT07282093Phase 1
• APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STRecruitingNCT06687070Phase 1
• Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingNCT06641414Phase 3
• A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Phase 3
• Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingNCT06423911Phase 3
• A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaRecruitingNCT06389292Phase 3
• A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingNCT06319456Phase 3
• A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.RecruitingNCT06182969Phase 1/2
• Global Trial in APG2575 for Patients With CLL/SLLRecruitingNCT06104566Phase 3
• A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingNCT06051409Phase 3
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.RecruitingNCT05773586Phase 1
• APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Phase 1/2
• Named Patient Program for Olverembatinib (HQP1351)AvailableNCT05594758
• Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasRecruitingNCT05415098Phase 1
• APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT05186012Phase 1/2
• Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT05147467Phase 2
• A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)RecruitingNCT04964518Phase 1/2
• APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT04942067Phase 1/2
• APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsRecruitingNCT04785196Phase 1/2
• A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis BRecruitingNCT04568265Phase 2
• Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingNCT04501120Phase 1/2
• A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingNCT04496349Phase 2
• Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT04494503Phase 1/2
• A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSRecruitingNCT04358393Phase 1/2
• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingNCT04275518Phase 1
• Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingNCT04260022Phase 1
• Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLRecruitingNCT04215809Phase 1
• APG-2449 in Patients With Advanced Solid TumorsRecruitingNCT03917043Phase 1
• A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Phase 1
• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesRecruitingNCT03537482Early Phase 1
• The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsCompletedNCT05517616Phase 1
• A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerSuspendedNCT04946864Phase 1/2
• A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsTerminatedNCT04893759Phase 1
• APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Phase 1/2
• APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaTerminatedNCT04643405Phase 1/2
• A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyWithdrawnNCT04354727Phase 1/2
• Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsTerminatedNCT04284488Phase 1/2
• APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaCompletedNCT04260217Phase 1
• Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT04210037Phase 1/2
• The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansCompletedNCT04126707Phase 1
• A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
• A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsActive, not recruitingNCT04001777Phase 1
• A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesActive, not recruitingNCT03913949Phase 1
• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationStatus unknownNCT03883087Phase 2
• Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1
• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2
• APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BCompletedNCT03585322Phase 1
• APG-1252 in Patients With SCLC or Advanced Solid TumorsTerminatedNCT03387332Phase 1
• APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesCompletedNCT03386526Phase 1
• A Study of APG-1252 in Patients With SCLC or Other Solid TumorsCompletedNCT03080311Phase 1
• APG-115 in Patients With Advanced Solid Tumors or LymphomasCompletedNCT02935907Phase 1

← Ascentage Pharma Group International overview and focus areas